# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Law Olmsted (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI022-SYN-TD
- Date: 1895-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathan Calder, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month dementia review. **S**

## History of present illness

Mr. Olmsted returns with his caregiver about six months after his first visit, twelve weeks after donepezil was increased to 10 mg each morning. He has had no nausea, diarrhea, dizziness, fainting, or vivid dreams, and his appetite is good. His memory is unchanged by his caregiver's account, and he enjoys the adult day program two days a week for its gardens. He has had no falls, no wandering, and no night-time confusion. His caregiver finished the education program, sleeps better, and has two free days a week. They went through the home safety checklist together this month: knob covers on the stove, locked medicines, and night lights on the way to the bathroom. **S**

| Element | Detail |
|---|---|
| Medicine | Donepezil 10 mg for twelve weeks; no side effects |
| Course | Memory unchanged; no new behavioral symptoms |
| Safety | No falls or wandering; home safety checklist completed |
| Caregiver | Education program completed; adult day program two days a week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea, diarrhea, or loss of appetite |
| Cardiovascular | Negative | No fainting or lightheadedness |
| Neurological | Positive | Memory loss unchanged; no falls |
| Psychiatric | Negative | Mood fair to good; no hallucinations or agitation; PHQ-9 score 4 |

4 systems reviewed. **S**

## Current medications

- Donepezil 10 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/76 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 71 kg; BMI 23.2 kg/m². All vital signs are synthetic.

PHQ-9: 4. All results are synthetic.

## Change since baseline

- PHQ-9: 6 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, pleasant, and engaged |
| Cardiovascular | Regular rhythm at 60 per minute; blood pressure 130/76 mmHg; weight 71.0 kg, stable since the wellness visit |
| Neurological | Oriented to person and place, not to date; no new focal signs; normal gait |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Mild dementia, type undetermined** (F03.A0). Stable clinically at CDR 1 on donepezil 10 mg, with heart rate 60, no fainting, and stable weight. Mood better (PHQ-9 4, from 6). Home safety and caregiver support in place. **S**
   - Continue donepezil 10 mg each morning.
   - Next dementia review in about three months, and the yearly review at one year from diagnosis with MoCA, ADL and IADL, CDR stage, and the Zarit Burden Interview.
   - Yearly behavioral neurology review, or sooner with a faster decline, new behavioral symptoms, or falls.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Medication review with the AGS Beers Criteria (anticholinergic burden, sedatives, sleeping pills, antipsychotics) | Every visit | Completed today | No anticholinergic, sedating, or other Beers-list drugs |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild apathy only; no hallucinations, agitation, wandering, or sleep disturbance |
| Medication safety | Cholinesterase inhibitor tolerability and benefit: heart rate, fainting, nausea, diarrhea, weight, sleep and dreams | Each follow-up on treatment | Completed today | On 10 mg for twelve weeks: heart rate 60, no fainting, no gastrointestinal effects, weight stable at 71.0 kg, no vivid dreams; stable course |
| Medication safety | Antipsychotic appropriateness and taper review | Every visit if on an antipsychotic | Not indicated | Not on an antipsychotic |
| Examination | Vascular risk-factor control (blood pressure, lipids, glucose, smoking) | Every visit | Completed today | Blood pressure 130/76 mmHg; LDL 118 mg/dL and statin decision at the wellness visit; never smoked |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Completed today | Checklist reviewed: stove knob covers, locked medicines, night lights; the review missed at three months is now done |
| Survey | Cognitive test (MoCA) | Annually; every visit if a change is reported | Up to date | MoCA 19 six months ago; no change reported; due at the yearly review |
| Survey | ADL (Katz) and IADL (Lawton-Brody) | Annually, and at any reported change | Up to date | No change reported; due at the yearly review |
| Survey | Dementia stage (CDR or FAST) | Annually | Up to date | CDR 1; due at the yearly review |
| Survey | Depression screen (PHQ-9) | Annually, and at any reported change | Completed today | PHQ-9 4, down from 6; no thoughts of self-harm |
| Examination | Fall-risk assessment (Timed Up and Go, gait and balance) | Annually | Up to date | Timed Up and Go 11 seconds six weeks ago; no falls |
| Examination | Driving safety (CDR-based) | At diagnosis and annually | Up to date | Not driving |
| Self-management | Firearms, wandering, and financial safety | At diagnosis and with any change | Completed today | No firearms; bracelet worn; no wandering; finances overseen |
| Survey | Caregiver burden (Zarit Burden Interview) and caregiver needs | At diagnosis, then every 6 to 12 months | Up to date | Zarit 24 three months ago; caregiver sleeping better with two free days a week; repeat at the yearly review |
| Self-management | Advance care planning and goals of care | At diagnosis, then annually and at stage changes | Up to date | Recorded three months ago and reviewed at the wellness visit |
| Laboratory | TSH, vitamin B12, blood count, and metabolic panel | At diagnosis; repeat only with acute cognitive worsening | Up to date | Normal at diagnosis; no acute change |
| Laboratory | Syphilis and HIV testing | Only with risk factors or atypical features | Not indicated | No risk factors |
| Imaging | Structural brain MRI, non-contrast | Once at diagnosis; repeat only with an atypical course or focal change | Up to date | Done once at diagnosis |
| Laboratory | Amyloid or tau biomarkers (blood, CSF, or amyloid PET) and APOE genotype | Before anti-amyloid therapy, or when the result would change care | Not indicated | Declined; no change in his wishes |
| Imaging | Anti-amyloid antibody therapy with ARIA surveillance MRI | Only if anti-amyloid therapy is started | Not indicated | Not chosen |
| Self-management | Lifestyle: aerobic exercise about twice a week, hearing, vision, sleep, social engagement | Ongoing | Completed today | Daily walks and the adult day program; hearing normal at the wellness visit; eye examination still to be booked |
| Referral | Dementia care navigation and caregiver support program | At enrollment, with ongoing support | Completed today | Education program completed; adult day program two days a week |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Up to date | Influenza, PCV20, and zoster dose 1 at the wellness visit; zoster dose 2 and Tdap due in the next four months |

## Goal progress

- Complete the reversible-cause tests and brain MRI and discuss the diagnosis with him and his caregiver by the four-week visit. Outcome by 1895-06-02: Tests and MRI showed no reversible cause; diagnosis of mild dementia of undetermined type discussed with both. **S**
- A safety plan in place by the three-month review: no driving, medicines supervised, finances overseen, and medical identification worn. Outcome by 1895-08-04: Stopped driving after the consultation; caregiver gives medicines from a weekly organizer and oversees bill paying with his agreement; medical identification bracelet worn. **S**
- Donepezil at 10 mg daily without side effects and with resting heart rate 55 or above by the six-month review. Outcome by 1895-10-27: On 10 mg for three months; heart rate 60; no nausea, diarrhea, weight loss, or vivid dreams. **S**
- Caregiver burden assessed and support in place by the six-month review. Outcome by 1895-10-27: Zarit Burden Interview 24 at three months; caregiver education program completed and two days a week of adult day program begun. **S**
- Name a health care agent and record his values and wishes while he can take full part, by the three-month review. Outcome by 1895-08-04: Health care agent named and his wishes recorded at the three-month review. **S**

## Guideline basis

- Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001), American Academy of Neurology (Neurology)
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025), Alzheimer's Association (Alzheimer's & Dementia)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026), Aether Forge

## Follow-up

- Dementia review in about three months; yearly review with MoCA, ADL and IADL, CDR stage, and the Zarit Burden Interview at one year from diagnosis. Second zoster dose and Tdap within the next four months. **S**

